Beloranib
Beloranib
Beloranib (pronunciation: bel-or-an-ib) is a metabolic drug that was under development for the treatment of obesity and associated co-morbidities, including type 2 diabetes. It was developed by Zafgen, a biopharmaceutical company based in Boston, Massachusetts.
Etymology
The term "Beloranib" is a coined name for the drug, with no known etymological roots.
Mechanism of Action
Beloranib works by inhibiting the enzyme methionine aminopeptidase 2 (MetAP2), which plays a key role in the regulation of fat metabolism. By blocking this enzyme, Beloranib reduces the production of new fatty acids and cholesterol in the body, leading to weight loss and improved metabolic control.
Clinical Trials and Controversies
Beloranib entered clinical trials in 2012. However, in 2016, the development of the drug was halted due to safety concerns after two patients died from pulmonary embolism during a phase 3 trial. The Food and Drug Administration (FDA) subsequently placed a complete clinical hold on the drug.
Related Terms
- Metabolic disorder
- Obesity
- Type 2 diabetes
- Methionine aminopeptidase 2
- Clinical trial
- Pulmonary embolism
- Food and Drug Administration
External links
- Medical encyclopedia article on Beloranib
- Wikipedia's article - Beloranib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski